FY2021 Earnings Forecast for VolitionRx Limited (NYSEAMERICAN:VNRX) Issued By Zacks Investment Research

VolitionRx Limited (NYSEAMERICAN:VNRX) – Investment analysts at Zacks Investment Research decreased their FY2021 earnings per share (EPS) estimates for shares of VolitionRx in a report issued on Monday, November 22nd. Zacks Investment Research analyst S. Ralston now expects that the medical research company will post earnings per share of ($0.50) for the year, down from their previous forecast of ($0.42). Zacks Investment Research also issued estimates for VolitionRx’s Q4 2021 earnings at ($0.14) EPS.

Separately, Aegis lowered their price target on shares of VolitionRx from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Tuesday, November 16th.

Shares of VolitionRx stock opened at $3.70 on Wednesday. VolitionRx has a 52-week low of $2.91 and a 52-week high of $6.67. The company has a current ratio of 4.17, a quick ratio of 5.44 and a debt-to-equity ratio of 0.12. The stock has a market cap of $198.08 million, a PE ratio of -8.04 and a beta of 1.74.

VolitionRx (NYSEAMERICAN:VNRX) last announced its quarterly earnings results on Wednesday, November 10th. The medical research company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). VolitionRx had a negative net margin of 28,471.43% and a negative return on equity of 100.42%.

In other VolitionRx news, CEO Salvatore Thomas Butera acquired 10,000 shares of the company’s stock in a transaction dated Tuesday, November 16th. The stock was bought at an average price of $4.02 per share, with a total value of $40,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 15.40% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Boothbay Fund Management LLC acquired a new stake in VolitionRx during the 2nd quarter valued at $38,000. Millennium Management LLC acquired a new stake in VolitionRx during the 1st quarter valued at $68,000. Jump Financial LLC acquired a new position in VolitionRx during the 2nd quarter worth $85,000. Dimensional Fund Advisors LP acquired a new position in VolitionRx during the 2nd quarter worth $88,000. Finally, Credit Suisse AG acquired a new position in VolitionRx during the 2nd quarter worth $104,000. 12.23% of the stock is owned by institutional investors and hedge funds.

About VolitionRx

VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on September 24, 1998 and is headquartered in Austin, TX.

Recommended Story: What is a Market Correction?

Earnings History and Estimates for VolitionRx (NYSEAMERICAN:VNRX)

Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.